Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000165439 | SCV000216168 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-02-25 | criteria provided, single submitter | clinical testing | The p.N2447D variant (also known as c.7339A>G), located in coding exon 13 of the BRCA2 gene, results from an A to G substitution at nucleotide position 7339. The asparagine at codon 2447 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000476866 | SCV000549659 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2024-01-28 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 2447 of the BRCA2 protein (p.Asn2447Asp). This variant is present in population databases (rs4986859, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 185933). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV001284102 | SCV001469708 | uncertain significance | not provided | 2020-01-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001284102 | SCV002601536 | uncertain significance | not provided | 2023-07-13 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as a germline pathogenic or benign variant to our knowledge; Also known as 7567A>G; This variant is associated with the following publications: (PMID: 31191615, 18724707) |
Baylor Genetics | RCV004567273 | SCV005059097 | uncertain significance | Familial cancer of breast | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004782270 | SCV005394945 | uncertain significance | not specified | 2024-09-11 | criteria provided, single submitter | clinical testing | Variant summary: BRCA2 c.7339A>G (p.Asn2447Asp) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251078 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.7339A>G in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 185933). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Sharing Clinical Reports Project |
RCV000238906 | SCV000297550 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2011-09-16 | no assertion criteria provided | clinical testing |